Enliven director receives 17,126 stock options

Enliven Therapeutics director Jake Bauer reported a new equity award.

Rhea-AI Filing Summary

Enliven Therapeutics director Jake Bauer reported a new equity award. He received a grant of stock options covering 17,126 shares at an exercise price of $0.00 per share. According to the terms, 100% of these options will vest on the earlier of the first anniversary of the 2026 annual stockholder meeting or the date of the 2027 annual stockholder meeting, as long as he continues serving as a non-employee director through that vesting date.

Insider Trade Summary

Grant/Award: 17,126 shares

Grant/Award 1 txn

Insider Bauer Jake

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	17,126	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 17,126 contracts (Direct)

Footnotes (1)

1. F1. 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2026 annual meeting of the Issuer's stockholders or (ii) the date of the 2027 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director through the applicable vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Enliven Therapeutics (ELVN) disclose for Jake Bauer?

Enliven Therapeutics disclosed that director Jake Bauer received a grant of stock options for 17,126 shares. The options were awarded at an exercise price of $0.00 per share as equity compensation for his role as a non-employee director.

How many Enliven Therapeutics (ELVN) options were granted to Jake Bauer?

Jake Bauer was granted stock options covering 17,126 Enliven Therapeutics shares. This award is recorded as a derivative security on the Form 4 and represents a new equity incentive tied to his ongoing service on the company’s board of directors.

What are the vesting terms for Jake Bauer’s Enliven Therapeutics stock options?

Jake Bauer’s options vest 100% on the earlier of the first anniversary of Enliven’s 2026 annual stockholder meeting or the date of the 2027 annual stockholder meeting. Vesting requires that he continue as a non-employee director through the applicable vesting date.

Did Jake Bauer buy or sell Enliven Therapeutics common shares in this Form 4?

No, Jake Bauer did not buy or sell common shares in this filing. The Form 4 reports an acquisition of derivative securities, specifically a grant of stock options, rather than an open-market purchase or sale of Enliven Therapeutics common stock.

What transaction code is used for Jake Bauer’s Enliven Therapeutics option grant?

The option grant to Jake Bauer is reported with transaction code “A,” indicating a grant, award, or other acquisition. This code is used when an insider receives securities from the issuer as compensation, rather than buying or selling them in the market.

Is Jake Bauer’s Enliven Therapeutics option award contingent on continued board service?

Yes, vesting of Jake Bauer’s options depends on continued service. All shares subject to the option vest only if he remains a non-employee director of Enliven Therapeutics through the earlier of the first anniversary of the 2026 annual meeting or the 2027 annual meeting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 07:56 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bauer Jake

(Last) (First) (Middle)

C/O ENLIVEN THERAPEUTICS, INC.

6200 LOOKOUT ROAD

(Street)

BOULDER CO 80301

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$27.16	02/12/2026		A		17,126		(1)	02/12/2036	Common Stock	17,126	$0	17,126	D

Explanation of Responses:

1. 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2026 annual meeting of the Issuer's stockholders or (ii) the date of the 2027 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director through the applicable vesting date.

	/s/ Ben Hohl, by power of attorney	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.